Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial. Braithwaite, I. E., Cai, F., Tom, J. A., Galanter, J. M., Owen, R. P., Zhu, R., Williams, M., McGregor, A. G., Eliahu, A., Durk, M. R., Dengler, H. S., Zak, M., Kenny, J. R., Wilson, M. E., Beasley, R., & Chen, H. Journal of Allergy and Clinical Immunology, March, 2021.
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial [link]Paper  doi  bibtex   
@article{braithwaite_inhaled_2021,
	title = {Inhaled {JAK} inhibitor {GDC}-0214 reduces exhaled nitric oxide in patients with mild asthma: {A} randomized, controlled, proof-of-activity trial},
	issn = {00916749},
	shorttitle = {Inhaled {JAK} inhibitor {GDC}-0214 reduces exhaled nitric oxide in patients with mild asthma},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S009167492100422X},
	doi = {10.1016/j.jaci.2021.02.042},
	language = {en},
	urldate = {2021-04-28},
	journal = {Journal of Allergy and Clinical Immunology},
	author = {Braithwaite, Irene E. and Cai, Fang and Tom, Jennifer A. and Galanter, Joshua M. and Owen, Ryan P. and Zhu, Rui and Williams, Mathew and McGregor, Anna G. and Eliahu, Avi and Durk, Matthew R. and Dengler, Hart S. and Zak, Mark and Kenny, Jane R. and Wilson, Maria E. and Beasley, Richard and Chen, Hubert},
	month = mar,
	year = {2021},
	pages = {S009167492100422X},
}
Downloads: 0